visit indeed.com/hire >>> breaking news on the fda panel booster vote meg terrell has the details. nel of outsider advisers has just voted down recommending a booster shot from pfizer's vaccine for people 16 and older. however, this is not necessarily going to be the final vote today on a booster shot. right now, this committee of outside experts is discussing whether they would be comfortable voting for perhaps a different age group. we just heard one expert on the panel say she might want to talk about recommending the booster for over age 50. and earlier, we heard one person maybe 60 or 65 and so right now, this is the question the panel was asked to vote on, whether they would recommend a booster dose based on the safety and efficacy data they've seen from pfizer, six months out for the primary vaccination, ages 16 plus. that has been voted down, but it's not the end of this story we'll go back to listening to what these experts are saying and let you know if they take another vote on a different age group. sara, back to you. >> keep us posted, meg meg, thank you meg terrell. we

meg terrel has more on that for us meg?e right now. there's been a lot of questions do the 14 million or so americans who've gotten j&j need a booster and if so, how much help does the booster give highly anticipated data on a trial when you give two shots of the j b & j vaccine out this morning from a press release from the company they space the doses out by two months the united states the efficacy against moderate or severe or critical covid went up to 94% when they gave these two doses two months apart globally that was 75%, perhaps reflecting some decreased efficacy because of variants around the globe they also said that the vaccine, quote, remained generally well tolerated in terms of that safety profile with two shots. now, the question here in the united states, though, for boosters is probably going to be 6 to 8 months out and j&j also looked at the antibody levels generated when you give the shots that far apart they said the six-month booster antibody levels go up 9 to 12 times compared to 4 to 6 times for a tw

cnbc's meg terrell covers the medical community for us did she make the right call? >> yeah. surprisingly, there's been a mixed reaction some say it was the right thing to do to bring the cdc's recommendation in line with the f.d.a.'s authorization others said she should have stuck with the committee's vote. i also spoke today with one of the advisors who had voted against boosters for all front line workers she is from wake forest. rather than feeling like she ignored the committee that instead she actually incorporated some of their concerns into the language of the recommendation specifically, saying those at exposure risk because of their jobs may receive a booster not that they should leaving the decision making up to them and their health care providers. but critics point out just the latest in a bumpy road to this point. just more than two months ago cdc and fda said definitively that americans do not need a booster shot at that time. just more than a month later, that big announcement that all americans should get one once they're eight months from being fully vaccina

meg terrel, thank you for bringing us the latest. >>> quick check on the markets to end the hour here the s&p down ever so slightly. the dow basically at the flat line the nasdaq, though, slightly higher that's going to do it for "squawk on the street. "techcheck" starts now ♪ ♪ >>> happy tuesday. welcome to "techcheck. today, the story was going to be a bounceback from yesterday's selloff, but that bounce has disappeared. all averages in the red or just about a flatline we're looking at semisoftware, big tech versus small and what moves kathy wood made to rebalance her portfolio yesterday. what should you do or not do in this market? we will discuss. >>> then, exclusive with the ceo of cyber security giant crowdstrike, as that company's stock quadrupled since its ipo finally, a check on apple. reviews of the iphone 13 are out today. ios 15 out, too. what apple's newest hardware and software will mean for the company and the stock. >> jon, we'll start with the continuation of this week's selloff. dow is down 40 points giving up all of their early gains this morning. that early rebound

raheem ma ellis from new york city meg terrell and the push back on booster shots. the fallout on the president's vaccine rules. you spoke to the labor secretary marty walsh today. what did he tell you >> shep, he said it's going to take a couple of weeks to right all of the rules i sat down with him on cnbc's capital exchange event and asked him to respond to the mounting opposition to the mandate. what would you say to some republicans or business groups that say this is it a government overreach? this is going too far? >> it's not about republicans, it's not about businesses, it's about everybody. i think businesses will welcome this businesses want to open. this is about keeping our economy afloat >> reporter: a recent poll shows a majority of voters agree with him. 62% agree. 36% are against it and 6% have no opinion economists predict many workers will comply. goldman sachs estimates 12 million more people will get vaccinated by next spring because of these new rules even if some people end up leaving their jobs in fact, i asked secretary walsh directly if com

. >>> we got breaking news on a treatment for covid-19 meg terrell joins us right now mech >> andrew,s on its drug ramdesivir they looked att patients at high risk of disease, similar for the monoclonal anti-body they found when they give it by iv for three days, it reduces the risk by 87% and saw a reduction in medical visits a month after given the treatment by placebo of course the monoclonal anti-bodies have seen massive increase in use as we seen that surge in cases across the south. this is three days of iv treatment. it's not as ease for going in once so gilead is up less than half a percent on this news. >> ramdesivir is the drug you have to start right away to have the best reaction to it. so it stops before you build up so many, before the virus can replicate quite as much and that's a tricky question who wants to sign up when they're not that sick yet f. are you a asymptomatic or lightly symptomatic, yes, i will get three days of an iv infusion in a hospital or hospital-like setting? >> yeah. that is the question how long will it take? how easy will it be to do that we have

>> in the meantime some encouraging news about the tests of the coronavirus vaccine in children meg terrellis the pfizer/biontech vaccine showing a strong immune response in kids 5 to 11 with one-third of the dose given to older people 12 and up they also said it was safe and well tolerated the side effects similar to what people 16 to 25 tend to experience pfizer telling us this morning they plan to start the application to the fda for emergency use authorization by the end of this month. pfizer's ceo in a tweet this morning said considering the rise of pediatric cases in covid and the substantial threat the delta variant poses to children, we're glad to share this news with the world they flplan to submit their dat for peer review. pediatric cases of covid have been on the rise, accounting for about 30% of all cases reported in the first week of september so the urgency here is growing becky. >> meg, thank you very much. >>> joining us right now for more on this is dr. scott gottlieb he's the former fda commissioner and a cnbc contributor who also serves on the boards not only of pfizer b

becky >>> two of the fda senior vaccine regau ulators are steppg down telling us what that means is meg terrellprocess take longer. >> these two officials announced their retirement mariann gruber is the head of fda's office of vaccines and research phil krause is the director. this came is raising questions my own reporting suggested there's some discold front, some discontent at the fda in how the white house handled the booster discuss. essentially coming out and saying people would have the opportunity to get boosters at the end of september before the fda has gone through the review process. also some reporting suggesting these folks might have been disgruntled over the cdc's role, front running the fda. i posed these questions at the white house covid briefing yesterday and asked if they are concerned about the pace of the approvals and trust in thefda. here's what he said. >> fda is the gold standard and we're all grateful for the tireless work of the senior team and the whole staff at fda, especially during the pandemic fda has strong leadership in dr. woodcock and peter marks >> acting

back to "squawk box" new data this morning on what drugs are being prescribed the most right now meg terrellwon't make them. it's interesting lipitor? what's prescribed the most >> you couldn't resist, joe. so we have new data from good rx exclusively provided to us this morning. looking back at the trends through the pandemic of which drugs are being used the most and what the trends look like and overall you can actually start to get a picture of when people started to get comfortable going back to the doctor's office for routine visits there's this category called low refill drugs those are prescriptions where you have to go back to the doctor for them to write you a refill it plunged in 2020 recovered in the end 2021 came back in february as vaccines started to roll out more broadly we talked with the director of good rx research about what she's seeing in that trend >> the fact we're seeing these low refill drugs return to normal means people are continuing to interact with their providers and they feel more comfortable now than they did during the pandemic to go in person, get these te